Business Update

PanGenomic Health Announces Financial Results for Half Year Ended June 30, 2023

August 30, 2023

VANCOUVER, BC, Aug. 30, 2023 /CNW/ – PanGenomic Health Inc. (“PanGenomic Health” or the “Company”) (CSE: NARA) (AQSE: NARA), is pleased to announce that it has filed financial statements for the six month period ended June 30, 2023 (the “First Half 2023 Financial  Statements”).

The First Half of 2023 Financial Statements, together with detailed information regarding the Company’s financial results as set forth in the Company’s management’s discussion and analysis for the same period can be found under the Company’s profile at

Key highlights in the period included:

  • Listed on the Aquis Stock Exchange (AQSE) in the United Kingdom.
  • Introduced hormonal health support for women with the availability of the Women’s Hormonal Health DNA Report.
  • Launched e-commerce platform to market its proprietary natural herbal remedy information library and practitioner-vetted brands.
  • Introduced rapid in-clinic access to patient Vitamin D assessments through the MUJN biomarker platform.
As at
PANGENOMIC HEALTH INC.Consolidated Statement of Financial Position(Expressed in Canadian Dollars)June 30,2023$December 31,2022$
Current assets
Cash and cash equivalents588,526
Amounts receivable74,792157,817
Prepaid expenses91,055204,103
Loan receivable33,08733,924
Total current assets198,939484,370
Non-current assets
 Total Assets215,705504,142
Current liabilities
Accounts payable and accrued liabilities804,251399,016
Loan payable500,000101,771
Due to related parties358,993218,465
Total liabilities1,663,244719,252
Common shares11,878,59511,240,056
Equity reserves3,675,0493,526,356
Total shareholders’ deficit(1,447,539)(215,110)
PANGENOMIC HEALTH INC.Six months ended June 30,
Consolidated Statement of Operations and Comprehensive Loss20232022
(Expressed in Canadian Dollars)$$
Advertising and promotion57,801200,604
Consulting fees560,401493,509
Director’s fees60,000
General and administrative87,05923,672
Professional fees258,909156,897
Research and development224,852351,144
Share-based compensation148,693202,215
Transfer agent and filing fees105,3368,382
Wages and benefits450,047182,008
Total expenses1,962,8461,629,677
Loss before other income (expense)(1,962,846)(1,629,677)
Other income (expense)
Interest expense(12,492)(57)
Interest income1,2391,410
Foreign exchange translation gain(9,334)(798)
Write-off of amounts receivable(36,228)
Total other income (expense)(56,815)555
Net loss and comprehensive loss for the period(2,019,661)(1,629,122)
Loss per common share, basic and diluted(0.02)(0.04)
Weighted average common shares outstanding98,981,91139,042,791
Consolidated Statement of Cash FlowJune 30,June 30,
(Expressed in Canadian Dollars)20232022
Operating activities
Net loss(2,019,661)(1,629,122)
Items not involving cash:
Foreign exchange translation loss (gain)837(542)
Share-based compensation148,693202,215
Write-off of amounts receivable36,228
Changes in non-cash operating working capital:
Amounts receivable46,297(50,038)
Prepaid expenses113,048102,875
Accrued interest receivable(7)
Accounts payable and accrued liabilities399,985175,159
Due to related parties155,428(860)
Net cash used in operating activities(1,112,997)(1,195,074)
Investing activities
Purchase of equipment(3,142)(3,445)
Net cash used in investing activities(3,142)(3,445)
Financing activities
Proceeds from issuance of units, net of issuance costs311,319
Proceeds from issuance of shares upon exercise of warrants327,220
Proceeds from units subscribed1,104,900
Proceeds from loans payable500,000
Repayment of loans payable(101,771)
Repayment of related party loans(9,150)
Net cash provided by financing activities1,027,6181,104,900
Change in cash(88,521)(93,619)
Cash and cash equivalents, beginning of period88,5261,348,622
Cash and cash equivalents, end of period51,255,003
Cash and cash equivalents consist of:
Cash in bank1,250,003
Bank indebtedness(11,245)
Cashable short-term investment certificate11,2505,000
Total cash and cash equivalents51,255,003
Non-cash investing and financing activities:
Issuance of common shares to acquire intangible asset75,000

About PanGenomic Health

PanGenomic Health is a precision health company that has developed a self-care digital platform to deliver personalized, evidence-based information about natural treatments. The Company’s initial focus is to support mental health. Registered as a British Columbia benefit company, PanGenomic Health’s mission is to promote and improve the health and wellness of people and society by providing a technology platform that identifies plant-based solutions tailored to the health profile of each individual.

Jerry Lai
Investor Relations
PanGenomic Health Inc.
778 743 4642

Maryam Marissen
President & CEO
PanGenomic Health Inc.
778 743 4642

This news release includes certain statements that may be deemed “forward-looking statements”, including statements respecting the services to be provided by PanGenomic Health and the consideration to be paid to PanGenomic Health. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “would”, “project”, “should”, “believe” and similar expressions are intended to identify forward looking statements. Although PanGenomic Health believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because PanGenomic Health can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this News Release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including those risk factors discussed in PanGenomic Health’s Management’s Discussion and Analysis (“MD&A”) for the year ended December 31, 2022, which can be found under PanGenomic Health’s profile on  Except as required under applicable securities legislation, PanGenomic Health undertakes no obligation to publicly update or revise forward-looking information.

The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.